mannose-1-phosphate
Orphan Drug Cold Chain RequiredInvestigational
Description
Mannose-1-phosphate is an investigational therapy for congenital disorders of glycosylation (CDG), specifically targeting MPI-CDG (CDG-Ib). It aims to bypass the enzymatic defect by providing the missing substrate for proper glycosylation. Clinical trials are ongoing to evaluate safety and efficacy in patients with CDG type II disorders.
Indications & Therapeutic Use
congenital disorders of glycosylation type II
Linked Diseases:
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
mannose-1-phosphate
| Generic Name | mannose-1-phosphate |
| Active Ingredient | mannose-1-phosphate |
| Drug Class | congenital disorders of glycosylation type II |
| Dosage Forms | IV infusion (investigational) |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 30 days |
| Reg. Status | Investigational |
| Clinical Trial | NCT02955264 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes